Personalized Medicine: AI’s Biological Revolution

The promise of personalization in medicine has echoed through the corridors of healthcare for a decade, a siren song for patients yearning for treatments tailored to their unique needs.

Yet, for millions, the reality remains a monotonous shuffle through standardized diagnostic routines, generic prescriptions, and predictable side effects.

This stark paradox defines much of AI-powered healthcare today: a technology lauded for its efficiency, but often failing to make care truly human.

It’s an illusion of individual attention, leaving patients feeling more like data points than people, a disquieting truth in an era of supposed innovation.

The core issue, experts contend, isn’t with artificial intelligence itself, but with the very fuel that powers it – the data.

Most AI models currently deployed in healthcare are trained on vast, population-level datasets: electronic health records, claims information, and symptom lists.

While these compilations are adept at revealing statistical trends across millions, they are largely blind to the intricate, dynamic biological realities unfolding within a single human body.

They can predict probabilities with impressive accuracy, but they struggle to grasp the ‘why’ – the underlying biological mechanisms that drive health and disease.

As Mika Newton, CEO of xCures, aptly put it, “AI will not transform healthcare if it operates in a vacuum.

AI requires the foundation of high-quality data, which begins with patients.”

This critical gap in personalization is precisely what a new wave of startups, such as California-based Parallel Health, are striving to bridge.

Their approach is fundamentally different: teaching AI to interpret biological data directly.

“Real personalization means treating you as a complex system, not a statistic,” explains Natalise Kalea Robinson, cofounder and CEO of Parallel Health.

She critiques the current state, where “most ‘personalized’ healthcare today is really just sophisticated segmentation — you’re placed in a bucket based on symptoms — sometimes demographics or genetic markers (if you’re lucky), then given the treatment that worked for most people in that bucket.”

It’s a pragmatic, albeit blunt, assessment of a system that often prioritizes broad applicability over individual specificity.

Parallel Health exemplifies this shift by anchoring its platform in biology, moving beyond the traditional reliance on medical records or demographics.

They employ quantitative whole-genome sequencing to meticulously map the trillions of bacteria, viruses, and fungi that constitute a person’s skin microbiome.

“This isn’t about comparing you to a population average — it’s about understanding your individual biological reality at the microbial level and at multiple points,” Robinson clarifies.

The implications are profound.

Consider two patients diagnosed with acne.

While their external symptoms may appear similar, their underlying causes can be dramatically different.

One might harbor an overgrowth of Cutibacterium acnes phylotype 1A, the usual suspect, while another could be battling antibiotic-resistant strains, explaining the futility of conventional treatments.

“No two ‘acne’ patients have the same skin microbiome; we have yet to see that across our incredibly large data set,” Robinson emphasizes, highlighting the sheer biological diversity.

This granular biological specificity allows Parallel to craft highly targeted phage serums, designed to eliminate only harmful microbial strains while preserving beneficial ones.

While independent researchers acknowledge the scientific promise of such precision, they also sound a note of caution, pointing to the steep regulatory, manufacturing, and standardization hurdles that phage therapy must overcome before widespread adoption.

Robinson, ever the pragmatist, acknowledges these challenges but pivots to a crucial point: adaptability, not just precision, will be the true arbiter of success.

“Your biology isn’t static, so your treatment shouldn’t be either,” she asserts.

“Real personalization is longitudinal, adaptive, and grounded in your actual biological data — not population proxies.”

For years, healthcare AI has been lauded for its prowess in pattern recognition – identifying tumors in scans, predicting hospital readmissions, and flagging anomalies in lab results.

However, Dr. Nathan Brown, Parallel Health’s chief science officer, argues that this is merely scratching the surface.

“Working with direct biological data transforms AI from a pattern-matching tool into a mechanistic prediction engine,” he states.

By analyzing the complex interplay between microbes and their human host, the system can begin to infer causality rather than mere correlation.

“Our AI can identify that specific microbial imbalances preceded symptom onset by months, enabling true prediction, not just early detection,” Brown notes, envisioning a future where AI shifts from reactive to truly preventive medicine.

The same microbial patterns signaling inflammation in acne, for instance, could hold clues for conditions like rosacea or certain types of psoriasis.

“What we learn about microbial dysbiosis in one condition can apply to others.

Our AI is learning fundamental principles of host-microbe interaction that generalize across diseases.

We then have the power to redefine complex diseases.”

While the potential of biology-driven AI systems, particularly those leveraging microbiome data, resonates with independent researchers, as noted in a review published in Nature, caution remains paramount.

The term “personalized” often conjures images of bespoke, hand-crafted medicine that seems inherently unscalable.

Dr. Seaver Soon, Parallel’s lead dermatologist and clinical advisor, challenges this notion.

“Personalization doesn’t mean we’re creating unique treatments for every individual from scratch,” he explains.

“We’re using platform technology to efficiently match patients to a bespoke solution from a defined toolkit.”

Parallel envisions its ‘toolkit’ as an expanding biobank of microbial strains and a refined manufacturing process for stabilizing targeted phage therapies – a significant hurdle the broader biomanufacturing industry is also racing to clear.

This model, reminiscent of the early days of genomic medicine when DNA sequencing was prohibitively slow and expensive but eventually became routine, hints at a future where microbiome-based care could follow a similar trajectory.

“Precision medicine eliminates trial and error,” Robinson explains, highlighting the economic and clinical benefits.

“If we can tell from the start that a patient’s bacteria are resistant to certain antibiotics, we can avoid treatments that won’t work, saving both time and cost.”

While research supports the potential for improved outcomes and reduced waste, a review in the Journal of Translational Medicine underscores that cost-effectiveness will ultimately hinge on reimbursement policies and equitable access – persistent barriers in clinical genomics.

As biology-driven AI gains momentum, critical questions concerning privacy and equity are rising to the forefront.

A report from the National Center for Biotechnology Information warned that the vast datasets integral to AI systems necessitate discussions about data ownership and management, emphasizing that data sovereignty – the right of individuals to control their biological data – will define the next phase of health innovation.

Robinson asserts that this principle is foundational to Parallel’s model.

“Patients must know what data is collected, how it will be used and what they get in return,” she states.

“Just because you can collect biological data doesn’t mean you should.”

For Robinson, transparency and equitable access are non-negotiable.

“The most dangerous risk in personalized medicine is creating a two-tier system where precision care is available only to the wealthy.

Communities that contribute data to our AI models must benefit from the resulting improvements.”

Bioethicists, including those contributing to a 2024 paper in BMC Medical Ethics and a 2025 study by the Committee on Data for Science and Technology, increasingly echo these concerns, stressing that the future of personalized medicine hinges not just on smarter algorithms, but on fairer systems built on trust, consent, and shared benefit.

Robinson frames this as a vital shift of power back to the patient, a much-needed correction in an era where data privacy remains a defining societal issue.

Ultimately, the true transformation of healthcare will depend on AI’s capacity to embrace and interpret the biological complexity of each individual, moving beyond statistical patterns to understand the unique human story.